ClinConnect ClinConnect Logo
Search / Trial NCT06324708

Analysis of Defined Elements on DXA in Patients Undergoing Hip Arthroplasty

Launched by I.R.C.C.S OSPEDALE GALEAZZI-SANT'AMBROGIO · Mar 14, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how certain imaging techniques can help doctors understand changes in bone health around the hip area after hip replacement surgery, also called hip arthroplasty. Researchers are looking at two specific measurements: bone mineral density (BMD), which tells us how strong the bone is, and the Bone Strain Index (BSI), which shows how much stress the bone can handle. By tracking these measurements over time, starting right after surgery and then again at six months, the study aims to see how the bones around the new hip joint change during recovery.

To participate in this trial, you need to be between 50 and 90 years old and scheduled for hip replacement surgery due to conditions like arthritis or hip joint deformities. The study is open to both men and women, but you should not have any serious infections, certain health conditions, or be taking specific medications that could affect your bone health. If you join the trial, you can expect to have your bone health monitored before and after your surgery, helping researchers learn more about how to improve outcomes for future patients undergoing similar procedures.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who are candidates for elective hip arthroplasty surgery (indication determined only by the Orthopedic Surgeon)
  • Patients with noninflammatory degenerative hip joint disease, including osteoarthritis and the outcomes of congenital hip dysplasia.
  • Hip joint deformity correction surgery
  • Patients aged 50 to 90 years (completed)
  • 18 ≤ Body Mass Index (BMI) ≤ 35 kg/m2
  • Postmenopausal women (absence of menstrual cycle for at least 2 years)
  • Willingness and ability to provide informed consent
  • Exclusion Criteria:
  • Taking drugs that may interfere with muscle or bone metabolism,
  • Evidence of diseases known to interfere with bone or muscle metabolism
  • Rheumatoid arthritis
  • Patients undergoing revision hip replacement surgery
  • Presence of infection or suspicion of infection at the hip
  • Inability to provide informed consent
  • Previous synthetic surgery for proximal femur fractures
  • Severe obesity (BMI \>35kg/m2)

About I.R.C.C.S Ospedale Galeazzi Sant'ambrogio

The I.R.C.C.S. Ospedale Galeazzi-Sant'Ambrogio is a leading clinical research institute and hospital in Italy, renowned for its commitment to advancing medical science through innovative research and high-quality patient care. As a designated Institute of Hospitalization and Care of Scientific Relevance (I.R.C.C.S.), it focuses on translational research that bridges the gap between laboratory findings and clinical applications. The facility is equipped with state-of-the-art technology and a multidisciplinary team of experts, enabling it to conduct a wide range of clinical trials aimed at improving treatment outcomes across various medical fields. Its dedication to ethical practices and patient safety ensures that all research activities align with the highest international standards.

Locations

Milan, , Italy

Patients applied

0 patients applied

Trial Officials

Laura Mangiavini

Principal Investigator

University of Milan, IRCCS Ospedale Galeazzi-Sant'Ambrogio

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported